Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study

Figures & data

Table 1 Demographic Characteristics of the Study Population

Characteristic	Number of Patients (Total 94)
Age (years)
Mean (±SD)	67.25 (10.25)
Gender
Males	63 (67.7%)
Females	31 (32.3%)
Treatment Status
Treatment-naive	20 (21.3%)
Previously treated	74 (78.7%)
Total number of prior injections in switch therapy group
Mean (±SD)	8.63 (4.74)
Total number of IVI brolucizumab per patient
Mean (±SD)	1.36 (± 0.58)
Interval between IVI brolucizumab in weeks
Mean (±SD)	10.2 ± 2.1

Abbreviations: SD, standard deviation; IVI, intravitreal injection.

Table 2 Differences in the Pre- and Post-Intravitreal Brolucizumab Injection Variables

Characteristic			Preinjection	Postinjection	P-value
LogMAR BCVA	Entire cohort	Mean (± SD)	0.81 (0.5)	0.66 (0.51)	<0.00001
	Treatment-naïve		0.41 (0.35)	0.36 (0.41)	0.36
	Switch Therapy		0.91 (0.49)	0.73 (0.51)	<0.00001
CST	Entire cohort	Mean (± SD)	408.45 (65.63)	281.14 (37.74)	<0.00001
	Treatment-naïve		398.53 (61.38)	285.16 (15.14)	<0.00001
	Switch Therapy		410.96 (66.42)	280.12 (41.5)	<0.00001

Abbreviations: LogMAR, Logarithm of the Minimum Angle of Resolution; BCVA, Best-corrected visual acuity; SD, Standard deviation; CST, Central subfield thickness.

Figure 1 Representative case of a treatment-naïve nAMD showing complete resolution of subretinal fluid along with significant reduction in the subretinal hyperreflective material (SHRM) at weeks 4 (B), 8 (C), and 12 (D) as compared to the baseline (A) after a single dose of intravitreal brolucizumab injection.

Figure 2 Representative case of nAMD who had previously received multiple anti-vascular endothelial growth factor (anti-VEGF) injections with suboptimal outcomes. After switching to intravitreal injection (IVI) brolucizumab, the patient demonstrated complete resolution of the subretinal and intraretinal fluid at weeks 4 (B) and 8 (C) as compared to the baseline (A). Early recurrence was noted at 12 weeks (D) for which the patient underwent second dose of IVI brolucizumab.

Table 3 List of Adverse Events in Patients Receiving Intravitreal Brolucizumab Injections

Adverse Event	Frequency (%)
Total	31 (24.6)
(Number of events/Total number of injections [126])
nsAE
(Number of events/Total number of injections [126])
Mild ocular Pain	18 (14.29%)
Burning sensation	6 (4.76)
Subconjunctival hemorrhage	4 (3.17)
Total	28 (22.22)
sADR (Ocular)
(Number of events/Total number of injections [126])
Subretinal hemorrhage	2 (1.59)
RPE tears	1 (0.79)
Total	3 (2.38)

Abbreviations: nsAE, Non-serious adverse events; sADR, Serious adverse drug reaction; RPE, Retinal pigment epithelium.